Takeda reports Phase 3 psoriasis data for zasocitinib

• Takeda (NYSE:TAK) reported new Phase 3 LATITUDE study data showing zasocitinib achieved higher skin clearance rates than deucravacitinib in adults with moderate-to-severe plaque psoriasis.
• In the LATITUDE Atlas trial, 36.5% of zasocitinib patients achieved complete skin clearance at Week 16 compared with 13.9% for deucravacitinib.
• Takeda stated that the results support further development of zasocitinib as a once-daily oral TYK2 inhibitor for psoriasis treatment.

Takeda (NYSE:TAK) announced Phase 3 LATITUDE study results for investigational drug zasocitinib (TAK-279), reporting statistically significant improvements compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis.

The LATITUDE Atlas head-to-head study compared zasocitinib with deucravacitinib, and Takeda reported higher rates of complete skin clearance, PASI 90 response and clear skin scores at Week 16, while previous psoriasis treatments included different oral therapeutic approaches.

"Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals," said Takeda Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit Chinwe Ukomadu, M.D., Ph.D.

The Phase 3 LATITUDE Atlas study included 301 patients receiving zasocitinib and 303 patients receiving deucravacitinib, with 36.5% achieving PASI 100 complete skin clearance versus 13.9% in the deucravacitinib group, while 62.5% achieved PASI 90 compared with 34.0%.

Additional Phase 3 LATITUDE PsO 3001 and 3002 data showed that up to 93% of patients who achieved a response at Week 24 maintained skin clearance through Week 52 in one post-hoc analysis, while patients also reported improvements in itch and quality of life.

Takeda is developing zasocitinib as an investigational oral TYK2 inhibitor for immune-mediated diseases, with ongoing research evaluating its safety and efficacy profile in psoriasis and other potential indications.